To date, most studies have associated ErbB3 and sErbB3 with breast and prostate cancers [31], [32] and there has been no report coupling these mediators with systemic inflammatory or gastrointestinal diseases in human. This evidence concerns the gene ERBB3 and gastrointestinal disease.